“Under the contract, QIMR’s intellectual property in the biomarkers will become licensed exclusively to Proteomics, which the company will use to develop and commercialise a simple blood test for the cancer“
“Proteomics says it will now undertake additional studies to confirm the diagnostic performance of the potential new blood test, which will take approximately six months“
Article: Proteomics International (ASX:PIQ) secures licence for oesophageal cancer biomarkers
